The Association of Patent Foramen Ovale and Migraine Headache
Study Prevalence # migraines % Closed % Migraine improved/cured Length of follow-up (months) Wilmshurst et al. (2000) [9] 21/37 59 86 30 Morandi et al. (2003) [10] 17/62 27 88…
ICE: Intra-Procedural Evaluation and Guidance During Closure of PFO
Fig. 6.1 Neutral or “Home” view: (a) 2 dimensional image of the tricuspid valve (arrow) and the LVOT coming into view. (b) Color Doppler through the tricuspid valve showing mild…
Optimal Device for Children and Closure Indications in Pediatric Population
Author, year Patient age (year) Number of patients Device Follow-up Closure rate Bartz et al. (2006) [33] 5–35 45 (42 with PFO) ASO (23) 5.3 months 98 % APFO (17)…
Obstructive Sleep Apnea and Patent Foramen Ovale
Fig. 14.1 Schematic representation of the relative changes in the intrathoracic pressure during normal respiration (a), the Valsalva maneuver (b), and the Mueller maneuver (c). i inspiration, e expiration, empty…
Obstacles in Starting a PFO Closure Program. How I Did It
1. Adequate training in PFO closure and preferably other structural heart procedures 2. Device manufacturer specific training on individual occluders 3. Adequate hospital privileges in place 4. Support from senior…
Clinical Trials to Assess the Relationship Between Patent Foramen Ovale and Migraine Headaches
Fig. 28.1 A patient with a CardioSeal device implanted 5 years previously: (a) TEE shows the device with the left atrial arms sticking up into the atrium. If there is…
PFO-Patient’s Perspective
Living with PFO What are my stroke risks due to PFO? What can I do to minimize these risks? What is the most effective medication to keep me from having…
From FDAs Point of View: What Is Needed to Move PFO Closure for Stroke Prevention Forward?
© Springer-Verlag London 2015Zahid Amin, Jonathan M. Tobis, Horst Sievert and John D. Carroll (eds.)Patent Foramen Ovale10.1007/978-1-4471-4987-3_25 25. From FDAs Point of View: What Is Needed to Move PFO Closure for Stroke Prevention Forward? Donald J. Hagler1 (1) Department…
The PC Trial: An Effective Treatment Not Demonstrating Effective Power
Endpoint PFO closure Medical therapy HR (95%CI) p-value Death (all cause) 1.0 0 5.20 (0.25–107) 0.95 Cardiovascular death 0 0 Stroke 0.5 2.4 0.20 (0.02–1.72) 0.14 TIA 2.5 3.3 0.71…
The Gore REDUCE Clinical Study
Inclusion criteria Patients (ages 18–60 years) with PFO who have a cryptogenic, ischemic stroke or imaging-confirmed TIA within 180 days prior to randomization All patients must have MRI evidence of…
